Compare Sana Biotechnology Inc (SANA) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Standard Lithium Ltd — how do they compare? Sana Biotechnology Inc trades at $2.79 (market cap $836.71M), while Standard Lithium Ltd trades at $1.58 (market cap $398.07M). The key difference: Sana Biotechnology Inc is far larger — about 2.1× Standard Lithium Ltd's market cap, and Sana Biotechnology Inc is more actively traded (4,507,444 versus 1,564,155). Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and Standard Lithium Ltd for 23 Days on average.
| SANA | SLI | |
|---|---|---|
Market Cap | $836.71M | $398.07M |
Volume | 4,507,444 | 1,564,155 |
Sector | Health | Basic Materials |
52-Week High | $5.92 | $5.65 |
52-Week Low | $2.68 | $1.61 |
Typical Hold Time | 23 Days | 23 Days |
Enterprise Value | $749.96M | $260.98M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
Standard Lithium (SLI) trades at $1.61, down 2.42% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company is pre-revenue with significant losses, reporting negative EBITDA of $50.53 million for 2025, but has made progress on its South West Arkansas lithium project, targeting a final investment decision by end of 2026. Analyst consensus is unanimously bullish with a $3.83 price target.
The investment case hinges on successful project execution and commercialization, offering substantial upside if milestones are met. Key risks include the capital-intensive nature of lithium production, execution delays, and reliance on future financing, with current cash flow sustained by financing activities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
